- Home
- SGD vs SLRX Comparison
SGD vs SLRX Comparison
Compare SGD & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- SLRX
- Stock Information
- Founded
- SGD 2021
- SLRX N/A
- Country
- SGD United States
- SLRX United States
- Employees
- SGD N/A
- SLRX N/A
- Industry
- SGD
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- SLRX Health Care
- Exchange
- SGD Nasdaq
- SLRX Nasdaq
- Market Cap
- SGD 2.6M
- SLRX 2.1M
- IPO Year
- SGD N/A
- SLRX N/A
- Fundamental
- Price
- SGD $1.28
- SLRX $1.34
- Analyst Decision
- SGD
- SLRX
- Analyst Count
- SGD 0
- SLRX 0
- Target Price
- SGD N/A
- SLRX N/A
- AVG Volume (30 Days)
- SGD 209.2K
- SLRX 71.1K
- Earning Date
- SGD 01-01-0001
- SLRX 03-21-2025
- Dividend Yield
- SGD N/A
- SLRX N/A
- EPS Growth
- SGD N/A
- SLRX N/A
- EPS
- SGD N/A
- SLRX N/A
- Revenue
- SGD $173,188.00
- SLRX N/A
- Revenue This Year
- SGD N/A
- SLRX N/A
- Revenue Next Year
- SGD N/A
- SLRX N/A
- P/E Ratio
- SGD N/A
- SLRX N/A
- Revenue Growth
- SGD N/A
- SLRX N/A
- 52 Week Low
- SGD $1.26
- SLRX $1.22
- 52 Week High
- SGD $53.80
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- SGD 33.74
- SLRX 32.32
- Support Level
- SGD $1.33
- SLRX $2.08
- Resistance Level
- SGD $1.46
- SLRX $1.94
- Average True Range (ATR)
- SGD 0.16
- SLRX 0.14
- MACD
- SGD 0.01
- SLRX -0.09
- Stochastic Oscillator
- SGD 3.74
- SLRX 2.80
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe & Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partner with third-party equity investors or other developers.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.